Oncology & Cancer

Sorafenib, sunitinib may pose cardiovascular risk

(HealthDay)—Older kidney cancer patients treated with sorafenib or sunitinib may face an increased risk of cardiovascular adverse events, according to a study published online Oct. 6 in Cancer.

Neuroscience

Stent restores speech and movement for 26-year-old stroke victim

The consequences of a stroke can last a lifetime. But for Isabel Vinueza, paralysis, blurred vision and slurred speech came and went in less than three hours thanks to an alert boyfriend and a new medical device that can ...

Cardiology

Clot-removal devices now recommended for some stroke patients

For the first time, the American Heart Association/American Stroke Association recommends using a stent retrieval device to remove blood clots in select stroke patients who have clots obstructing the large arteries supplying ...

Cardiology

Effectiveness of new stroke treatment confirmed

A research paper published in the New England Journal of Medicine (NEJM) today confirms earlier findings that a procedure called endovascular therapy (ET) for ischemic stroke is the best treatment option for many patients ...

page 15 from 31